The EBODAC project (Ebola Vaccine Deployment, Acceptance and Compliance) is developing strategies and tools to promote the acceptance and uptake of new Ebola vaccines, to help the right person receive the right vaccine at the right time.


EBODAC is important because the successful development and deployment of an Ebola vaccine is faced with many challenges, especially when working in resource limited settings. These include:


EBODAC is working to ensure the prime-boost vaccine regimen is well accepted and successfully used in the context of clinical trials; while also preparing to maximise the impact of the potential deployment of a future Ebola vaccination programme in West Africa.

EBODAC is currently supporting the EBOVAC-Salone clinical trial in Kambia District, Sierra Leone, and is using this opportunity to evaluate the three levers it has developed:


All components of the EBODAC platform are designed and developed to allow rapid scale-up should there be a need to eventually deploy a licensed vaccine.

Learn more about EBODAC with our short Introduction to EBODAC animation.

These projects have received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOMAN (grant nr. 115850) and EBODAC (grant nr. 115847). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations (EFPIA).
Copyright © 2018 Ebovac | Terms and Conditions | WordPress development by Toast.